The article focuses on the treatment of metastasized breast cancer. As stated, there has been a lot of development in therapeutic strategies in terms of antibodies and tyrosine kinase inhibitors (TKI). It is believed that over the time of treatment there is no difference in outcome between sequential monotherapy and combination therapies, but the risk for major side effects is higher with combinations.